Stay Ahead of Medical Breakthroughs with Expert Insights and Email Alerts

Key findings highlighted:

• ET-02 targets dysfunctional hair follicle stem cells, addressing the underlying cause of androgenic alopecia.
• The treatment has shown promise in restoring hair growth and normalizing hair follicle function.

Eirion Therapeutics has initiated a phase 1 study to evaluate the safety of ET-02 for treating androgenic alopecia, enrolling its first participant.

ET-02 is a topical treatment designed to restore hair growth by addressing the root cause of age-related hair loss in men.

“Preliminary studies have demonstrated ET-02's potential to restore hair growth and normalize hair follicle function, offering a novel approach to addressing the fundamental cause of androgenic alopecia,” Jon Edelson, MD, CEO and president of Eirion, noted.

Eirion believes that ET-02's unique mechanism of action positions it as a more effective treatment option compared to existing therapies.

The company also anticipates that ET-02 will not cause side effects commonly associated with hormonal treatments, such as sexual dysfunction.

The double-blind, placebo-controlled study aims to evaluate the safety of once-daily ET-02 treatment over 28 days in approximately 24 participants across three U.S. centers.

Eirion also intends to explore the potential of ET-02 in preventing hair greying, an indication that may be pursued in future studies.

Rubenhair Clinic - Hair Transplant in Latvia. Learn more about our hair transplant services.